Tarlatamab
Jump to navigation
Jump to search
 | An editor has performed a search and found that sufficient sources exist to establish the subject's notability. (January 2024) |
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Clinical data | |
| Other names | AMG757; AMG-757 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
Tarlatamab is a bispecific T cell engager that binds DLL3 and CD3 which has shown promise for previously treated small cell lung cancer.[1]
References
- ^ Ahn, Myung-Ju; Cho, Byoung Chul; Felip, Enriqueta; Korantzis, Ippokratis; Ohashi, Kadoaki; Majem, Margarita; Juan-Vidal, Oscar; Handzhiev, Sabin; Izumi, Hiroki; Lee, Jong-Seok; Dziadziuszko, Rafal; Wolf, Jürgen; Blackhall, Fiona; Reck, Martin; Bustamante Alvarez, Jean (2023-11-30). "Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer". New England Journal of Medicine. 389 (22): 2063–2075. doi:10.1056/NEJMoa2307980. ISSN 0028-4793.
 | This medical article is a stub. You can help Wikipedia by expanding it. |
Categories:
- Articles with short description
- Short description is different from Wikidata
- Articles needing additional references from January 2024
- All articles needing additional references
- Drugs with non-standard legal status
- Infobox drug articles with non-default infobox title
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Drugs missing an ATC code
- Articles containing unverified chemical infoboxes
- Drugs that are a monoclonal antibody
- All stub articles
- Medicine stubs
- Experimental cancer treatments
- Experimental cancer drugs
- Lung cancer